INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $273,557 | +9.9% | 14,755 | -34.4% | 0.00% | – |
| Q2 2023 | $248,839 | -93.0% | 22,499 | -91.5% | 0.00% | -100.0% |
| Q1 2023 | $3,559,716 | +215.5% | 265,057 | +190.6% | 0.00% | +100.0% |
| Q4 2022 | $1,128,454 | -2.4% | 91,225 | +10.1% | 0.00% | 0.0% |
| Q3 2022 | $1,156,000 | +29.3% | 82,871 | +28.0% | 0.00% | – |
| Q2 2022 | $894,000 | +260.5% | 64,760 | +324.9% | 0.00% | – |
| Q1 2022 | $248,000 | -12.1% | 15,241 | -12.1% | 0.00% | – |
| Q4 2021 | $282,000 | -26.2% | 17,333 | -32.8% | 0.00% | – |
| Q3 2021 | $382,000 | -83.9% | 25,782 | -78.2% | 0.00% | -100.0% |
| Q2 2021 | $2,366,000 | +265.1% | 118,509 | +321.5% | 0.00% | – |
| Q1 2021 | $648,000 | -64.1% | 28,115 | -61.5% | 0.00% | -100.0% |
| Q4 2020 | $1,803,000 | -85.9% | 72,980 | -76.4% | 0.00% | -88.9% |
| Q3 2020 | $12,811,000 | -13.2% | 308,989 | +0.3% | 0.01% | -18.2% |
| Q2 2020 | $14,765,000 | -35.0% | 308,163 | -14.6% | 0.01% | -45.0% |
| Q1 2020 | $22,726,000 | -62.8% | 360,960 | -26.7% | 0.02% | -50.0% |
| Q4 2019 | $61,026,000 | +166.2% | 492,478 | +42.5% | 0.04% | +150.0% |
| Q3 2019 | $22,929,000 | -38.9% | 345,558 | -26.8% | 0.02% | -27.3% |
| Q2 2019 | $37,541,000 | -13.1% | 471,841 | +22.2% | 0.02% | -15.4% |
| Q1 2019 | $43,193,000 | +15.9% | 386,158 | +4.5% | 0.03% | 0.0% |
| Q4 2018 | $37,253,000 | -68.0% | 369,619 | -59.9% | 0.03% | -23.5% |
| Q3 2018 | $116,489,000 | +94.2% | 921,894 | +29.0% | 0.03% | +100.0% |
| Q2 2018 | $59,985,000 | +237.9% | 714,892 | +147.7% | 0.02% | +112.5% |
| Q1 2018 | $17,751,000 | +93.1% | 288,603 | +83.3% | 0.01% | +33.3% |
| Q4 2017 | $9,193,000 | -25.0% | 157,426 | -25.5% | 0.01% | -25.0% |
| Q3 2017 | $12,263,000 | -44.9% | 211,332 | +14.9% | 0.01% | -50.0% |
| Q2 2017 | $22,261,000 | +10.9% | 183,878 | +3.6% | 0.02% | +6.7% |
| Q1 2017 | $20,067,000 | +1.5% | 177,444 | -2.5% | 0.02% | -6.2% |
| Q4 2016 | $19,770,000 | -45.7% | 181,983 | -17.8% | 0.02% | -38.5% |
| Q3 2016 | $36,423,000 | +1.7% | 221,316 | -11.8% | 0.03% | +4.0% |
| Q2 2016 | $35,798,000 | +85.3% | 250,921 | +66.8% | 0.02% | +66.7% |
| Q1 2016 | $19,322,000 | -32.6% | 150,420 | -21.7% | 0.02% | -25.0% |
| Q4 2015 | $28,672,000 | +0.2% | 191,994 | +11.2% | 0.02% | -9.1% |
| Q3 2015 | $28,621,000 | -32.7% | 172,583 | -2.1% | 0.02% | -18.5% |
| Q2 2015 | $42,558,000 | +13.1% | 176,321 | +32.1% | 0.03% | +17.4% |
| Q1 2015 | $37,633,000 | +415.3% | 133,451 | +185.0% | 0.02% | +360.0% |
| Q4 2014 | $7,303,000 | +72.3% | 46,823 | +161.5% | 0.01% | +66.7% |
| Q3 2014 | $4,238,000 | +6.9% | 17,908 | +6.8% | 0.00% | 0.0% |
| Q2 2014 | $3,965,000 | +53.4% | 16,765 | +113.9% | 0.00% | +50.0% |
| Q1 2014 | $2,584,000 | +2591.7% | 7,839 | +453.2% | 0.00% | – |
| Q4 2013 | $96,000 | -84.5% | 1,417 | -84.3% | 0.00% | – |
| Q3 2013 | $621,000 | – | 9,014 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |